---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-008188"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T12:30:16.688657+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# DiaMedica reports FY2022 cash $33.5M, updates on ReMEDy2 clinical hold progress

## Summary
- Cash and investments of $33.5M at Dec 31, 2022 vs $45.1M at end of 2021; cash runway into Q4 2024.
- R&D expenses fell to $7.8M in 2022 from $8.8M; G&A expenses rose to $6.2M from $4.9M.
- FDA clinical hold on ReMEDy2 remains; Part 1 in-use study completed, supports dose revision to avoid hypotension; Part 2 data due April 2023.
- Phase 1C SAD study of DM199 started in Australia to confirm IV dose; enrollment underway, preliminary data expected May 2023.

## SEC filing metadata
- accession: 0001437749-23-008188
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774923008188/0001437749-23-008188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774923008188/dmtp20230327_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-008188
- JSON: https://secwatch.observer/filing/0001437749-23-008188.json
- Plain text: https://secwatch.observer/filing/0001437749-23-008188.txt

## Key facts
- Earnings Releases
  DiaMedica Therapeutics Inc. reported financial results for for the year ended December 31, 2022.
  - Period: for the year ended December 31, 2022
  - Result: reported results
  source text: On March 28, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774923008188/0001437749-23-008188-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.